SCHEMBL3227578

SCHEMBL3227578

CCN(c1nc(-c2ccc(F)c(F)c2)c2ccc(=O)n(-c3ccc(C(F)(F)F)cc3)c2n1)C(O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.35
USP2 O75604 3/20 0.33
CYP1A2 P05177 3/20 0.33
CYP3A4 P08684 3/20 0.33
CRHR1 P34998 2/20 0.33
TSHR P16473 1/20 0.33
MEN1 O00255 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
TRPV4 Q9HBA0 1/20 0.32
PTGS2 P35354 1/20 0.32
PIK3CA P42336 4/20 0.31
TRPV3 Q8NET8 2/20 0.31
TRPV1 Q8NER1 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HSD17B10 Q99714 1/20 0.31
MCHR1 Q99705 1/20 0.30
DHFR P00374 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3229356 0.90 MEN1 (0.35) USP2CYP1A2CYP3A4CRHR1MEN1
SCHEMBL3221957 0.88 CYP1A2 (0.39) TRPA1USP2CYP1A2CYP3A4CRHR1
SCHEMBL3224069 0.85 PTGS2 (0.35) CRHR1PTGS2MTOR
SCHEMBL3216354 0.82 CNR1 (0.37) CYP3A4TSHRMEN1CYP2C9KMT2A
SCHEMBL3228078 0.82 CRHR1 (0.34) CRHR1TRPV4TRPV1
SCHEMBL3230739 0.80 TRPV1 (0.40) TSHRPTGS2TRPV1PTGDR2HSD17B10
SCHEMBL3229360 0.78 CXCR3 (0.36) USP2CYP1A2CYP3A4MEN1KMT2A
SCHEMBL3221968 0.77 TRPA1 (0.37) TRPA1USP2CYP1A2CYP3A4TSHR
SCHEMBL3228986 0.77 IDH2 (0.37) TRPA1USP2CYP1A2CYP3A4TSHR
SCHEMBL4938981 0.75 GRIN1 (0.32) GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069409-A1 \"NOVEL COMPOUNDS\ GLAXO GROUP LIMITED (GB) 2010-03-18 US disclosed
US-7479558-B2 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives GLAXO GROUP LIMITED (GB) 2009-01-20 US disclosed
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives GLAXO GROUP LIMITED (GB) 2008-04-24 US disclosed
EP-1865959-A2 PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2007-12-19 EP disclosed
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives GLAXO GROUP LIMITED (GB) 2006-11-16 US disclosed
WO-2006104917-A2 PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives CBR3, CBR1, CYP2S1 TRPA1 2617/4885USP2 4259/4885CYP1A2 104/4885
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives CYP2S1, CYP2F1, CBR3 TRPA1 2722/4885USP2 4284/4885CYP1A2 64/4885
US-20100069409-A1 \"NOVEL COMPOUNDS\ MAPKAPK2, CDC42BPB, MAP4K2 TRPA1 2723/4885USP2 2790/4885CYP1A2 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.